Rapid growth for Pacira Pharmaceuticals' (NASDAQ:PCRX) time-release surgical painkiller Exparel is lifting profit as sales are leveraged against fixed costs, but a bigger opportunity may be ahead if the company can execute on plans to boost Exparel's addressable market. If so, the rapid run-up in Pacira Pharmaceuticals shares in October may be the start, rather than the end, for this company.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24%
Despite a mixed third-quarter report, Pacira topped Wall Street's expectations where it counts.
Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
Disappointing late-stage trial data is dashing investor optimism.
4 Small-Cap Stocks Set to Grow EPS by at Least 400% Through 2020
You'd struggle to find faster-growing small-cap stocks.